{"entity":{"id":"nct07750041","kind":"trial","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of bevacizumab (glioblastoma use) and regorafenib in colorectal cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","summary":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07750041 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 260 participants, started 2026-08-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYS6090 (Fixed Dose Level A) + bevacizumab; SYS6090 (Fixed Dose Level B ) + bevacizumab; SYS6090 RP2D + bevacizumab +mFOLFOX6; SYS6090 RP2D + bevacizumab; Regorafenib; SYS6090 PR2D+ bevacizumab + FOLFOXIRI; bevacizumab + FOLFOXIRI. Conditions listed: Unresectable Advanced or Metastatic Colorectal Cancer. Primary outcome: Recommended Phase 2 Dose (RP2D), Safety and Tolerability; Objective Response Rate (ORR) assessed per RECIST v1.1; Progression-Free Survival (PFS) assessed per RECIST v1.1. Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed unresectable advanced or metastatic colorectal cancer with pMMR/MSS status, assigned to corresponding cohorts as follows:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07750041","url":"https://clinicaltrials.gov/study/NCT07750041"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07750041","phase":"1/2","setting":"A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Coloretal Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":260,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07750041/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}